|Bid||182.41 x 200|
|Ask||182.94 x 100|
|Day's Range||181.29 - 184.82|
|52 Week Range||133.64 - 191.10|
|PE Ratio (TTM)||16.66|
|Earnings Date||Oct 25, 2017|
|Forward Dividend & Yield||4.60 (2.51%)|
|1y Target Est||190.50|
Carter Worth, Cornerstone Macro, discusses how the health care sector is starting to heat up. The “Fast Money” traders weigh in.
In highlights from this week's trading diary and posts, Kass discusses risk and how it differs from risk awareness.
THOUSAND OAKS, Calif., Oct. 20, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its third quarter financial results on Wednesday, Oct. 25, 2017, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors.
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
CAMBRIDGE, Mass., Oct. 16, 2017 /PRNewswire/ -- Amgen (AMGN) and Boston Children's Hospital today announced that they have entered into a neuroscience research collaboration aimed at identifying novel pain targets based on human genetic analyses. The one-year collaboration will focus on patients with genetic anomalies of pain sensitivity. Amgen will leverage its industry-leading expertise in genetic target identification and validation and will have access to Boston Children's Hospital's Division of Pain Medicine to identify patients with abnormal pain conditions.
Credit Suisse's Alethia Young and her team take a look at the biotech sector ahead of earnings, writing that they expect large-cap companies' strength to continue through the end of the year. Young writes that she expects most companies to be either in-line or above consensus estimates when they report third-quarter results, as large cap biotechs have been strong heading into t he third quarter. Among stocks where she has the most conviction in the quarter, she thinks that Biogen (BIIB) can beat expectations thanks to Spinraza (it's spinal muscular atrophy drug) trends in the U.S. She writes that she thinks investors should expect a "solid" quarter from Bioverativ (BIVV) as well, and will also be focusing on sales from Regeneron's (REGN) Dupixent and Gilead's (GILD) HCV franchise.
THOUSAND OAKS, Calif. and MOUNTAIN VIEW, Calif., Oct. 12, 2017 /PRNewswire/ -- The Amgen Foundation today announced a three-year, $3 million grant to Khan Academy to develop comprehensive new biology lessons. The Amgen Foundation is the exclusive sponsor of Khan Academy's biology content. With the Amgen Foundation's support, Khan Academy will create new biology lessons for students and teachers worldwide.
Dow component Merck said late Wednesday it won't submit applications for approval of a cholesterol drug.
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
Biosimilar drugmakers are eager to launch competitors to Amgen's drugs, but one big competitor is going to have to wait a while longer.
Continuity efforts at Amgen's Puerto Rico drug manufacturing plant reveal the dedication of the island's workers in the pharmaceutical and medical device industries.
Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).
EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.
Aimovig is the only biologic product under investigation that has been designed specifically to prevent a migraine by inhibiting the CGRP (calcitonin gene-related peptide) receptor.
THOUSAND OAKS, Calif., Oct. 9, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The sBLA, which was submitted on July 28, 2017, is based on a Phase 3 study evaluating Prolia compared with risedronate in patients receiving glucocorticoid treatment. Glucocorticoid medications, which are used to treat many inflammatory conditions, can cause significant side effects, including bone loss.
Gabelli & Co. We reiterate a Buy rating on Regeneron Pharmaceuticals with an estimated 2018 private market value of $554 a share. On Oct. 5, Regeneron (REGN) announced that the appeals court has removed the permanent injunction on Praluent. The injunction was issued in January to block sales of Praluent, after a federal jury ruled against Regeneron in patent litigation and declared two of Amgen’s (AMGN) patents linked to PCSK9 in March 2016 valid.
In September 2017, Amgen and Allergan presented results from the Phase 3 trial, which evaluated the safety and efficacy of ABP 980, a proposed biosimilar to Herceptin.
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.